Roivant Sciences (NASDAQ:ROIV) Director Daniel Allen Gold Sells 425,000 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Daniel Allen Gold sold 425,000 shares of the company’s stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $26.67, for a total value of $11,334,750.00. Following the completion of the transaction, the director directly owned 15,928,113 shares in the company, valued at $424,802,773.71. This represents a 2.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Daniel Allen Gold also recently made the following trade(s):

• On Friday, February 13th, Daniel Allen Gold sold 375,784 shares of Roivant Sciences stock. The shares were sold at an average price of $26.50, for a total value of $9,958,276.00.
• On Wednesday, December 17th, Daniel Allen Gold sold 777,332 shares of Roivant Sciences stock. The stock was sold at an average price of $23.07, for a total transaction of $17,933,049.24.
• On Tuesday, December 16th, Daniel Allen Gold sold 917,282 shares of Roivant Sciences stock. The shares were sold at an average price of $23.04, for a total value of $21,134,177.28.
• On Wednesday, November 19th, Daniel Allen Gold sold 1,300,000 shares of Roivant Sciences stock. The stock was sold at an average price of $20.23, for a total transaction of $26,299,000.00.

Roivant Sciences Stock Down 1.1%

Shares of NASDAQ:ROIV traded down $0.30 on Friday, reaching $26.45. The company had a trading volume of 4,357,971 shares, compared to its average volume of 6,771,100. The stock has a market capitalization of $18.40 billion, a P/E ratio of -22.61 and a beta of 1.22. The stock has a 50-day moving average price of $22.71 and a 200 day moving average price of $18.31. Roivant Sciences Ltd. has a twelve month low of $8.73 and a twelve month high of $27.94.

Key Roivant Sciences News

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Multiple analysts raised price targets and maintained bullish ratings (HC Wainwright, Goldman Sachs, Leerink, Citi — consensus PT ~ $28.69), supporting a positive headline narrative for the stock. MarketBeat ROIV coverage
• Positive Sentiment: Institutional flows show new and increased positions (several funds added ROIV, LPL Financial materially increased its stake), which can provide demand support below recent highs. MarketBeat institutional ownership report
• Neutral Sentiment: HC Wainwright slightly improved its FY2026 EPS view (less negative) and kept a Buy rating with a $33 target — this is mixed for stock moves because estimates remain negative even as the price target was raised. HC Wainwright note
• Negative Sentiment: Director Daniel Allen Gold sold two large blocks (425,000 shares on Feb 11 and 375,784 shares on Feb 13) at ~ $26.50 per share (SEC filing). Large director sales can create near‑term selling pressure and raise investor caution. SEC filing — Daniel Gold sales
• Negative Sentiment: Insider Mayukh Sukhatme sold 339,441 shares on Feb 9 at ~$26.47; this is another sizable insider disposition following previous large sales, which may weigh on sentiment. InsiderTrades / sale report
• Negative Sentiment: HC Wainwright cut several 2027 quarterly EPS forecasts and lowered FY2027 EPS materially (from about -$1.22 to -$1.79), signaling expectations for weaker near‑term financial performance — a clear negative for sentiment until operational catalysts emerge. HC Wainwright estimate update

Hedge Funds Weigh In On Roivant Sciences

Several institutional investors have recently bought and sold shares of the business. Penn Davis Mcfarland Inc. lifted its stake in shares of Roivant Sciences by 10.1% in the 3rd quarter. Penn Davis Mcfarland Inc. now owns 1,862,088 shares of the company’s stock valued at $28,173,000 after purchasing an additional 170,456 shares during the period. Valeo Financial Advisors LLC acquired a new stake in shares of Roivant Sciences during the second quarter worth $1,145,000. IFG Advisory LLC bought a new stake in Roivant Sciences in the second quarter valued at about $255,000. Y Intercept Hong Kong Ltd bought a new stake in Roivant Sciences in the second quarter valued at about $3,064,000. Finally, iSAM Funds UK Ltd lifted its stake in Roivant Sciences by 244.8% in the second quarter. iSAM Funds UK Ltd now owns 137,468 shares of the company’s stock valued at $1,549,000 after buying an additional 97,600 shares during the period. Institutional investors own 64.76% of the company’s stock.

Wall Street Analysts Forecast Growth

ROIV has been the topic of a number of research reports. Jefferies Financial Group reaffirmed a “buy” rating and set a $30.00 target price on shares of Roivant Sciences in a research report on Monday. Leerink Partners raised their price target on shares of Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a research report on Monday, December 15th. Weiss Ratings downgraded shares of Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday. HC Wainwright increased their target price on shares of Roivant Sciences from $26.00 to $33.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Wall Street Zen raised Roivant Sciences from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.69.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.